ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
  • Abstract Number: 489
    S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)
  • Abstract Number: 527
    Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
  • Abstract Number: 867
    Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
  • Abstract Number: 865
    Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
  • Abstract Number: 2843
    Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
  • Abstract Number: L12
    Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
  • Abstract Number: 2877
    Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
  • Abstract Number: 1800
    Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)
  • Abstract Number: 712
    Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
  • Abstract Number: 2093
    Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases
  • Abstract Number: 2375
    Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
  • Abstract Number: 2360
    Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
  • Abstract Number: 2529
    Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis
  • Abstract Number: 2152
    Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases
  • Abstract Number: 850
    Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
  • Abstract Number: 1804
    Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients
  • Abstract Number: 1525
    Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
  • Abstract Number: 847
    Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
  • Abstract Number: 1503
    Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
  • Abstract Number: 509
    Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
  • Abstract Number: 1326
    Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
  • Abstract Number: 2547
    Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use
  • Abstract Number: 2530
    Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
  • Abstract Number: 2574
    Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters
  • Abstract Number: 1325
    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA
  • Abstract Number: 2175
    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study
  • Abstract Number: L05
    Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
  • Abstract Number: 1450
    Salivary Gland Hypofunction in a Mouse Model for Sjögren’s Syndrome Is Strongly Associated with Hyperglycemia
  • Abstract Number: 906
    Sarcoidosis as a Systemic Disease. Clinical and Epidemiological Characterization of Systemic Phenotype in 1521 Patients
  • Abstract Number: 2177
    Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study
  • Abstract Number: 1657
    Sarcopenia in Systemic Sclerosis
  • Abstract Number: 569
    Sarcopenia, Segmental Muscle Strength and Body Composition in Young Axial Spondylarthritis Patients: Results from MyoSpA Study
  • Abstract Number: 1398
    Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
  • Abstract Number: 2710
    Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
  • Abstract Number: 1920
    School Nurse Education for Juvenile Idiopathic Arthritis
  • Abstract Number: 2124
    Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?
  • Abstract Number: 313
    Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
  • Abstract Number: 2100
    Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients
  • Abstract Number: 2589
    Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index
  • Abstract Number: 399
    Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
  • Abstract Number: 380
    Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution
  • Abstract Number: 398
    Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
  • Abstract Number: 702
    Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort
  • Abstract Number: 14
    Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis
  • Abstract Number: L21
    Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
  • Abstract Number: 1557
    Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
  • Abstract Number: 2880
    Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
  • Abstract Number: 2709
    Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index
  • Abstract Number: 1485
    Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study
  • Abstract Number: 1482
    Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
  • Abstract Number: 98
    Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
  • Abstract Number: 85
    Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
  • Abstract Number: 1366
    Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?
  • Abstract Number: 2272
    Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies
  • Abstract Number: 208
    Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)
  • Abstract Number: 980
    Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis
  • Abstract Number: 818
    Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis
  • Abstract Number: 1291
    Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
  • Abstract Number: 2848
    Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
  • Abstract Number: 1982
    Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain
  • Abstract Number: 901
    Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study
  • Abstract Number: 666
    Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
  • Abstract Number: 1660
    Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
  • Abstract Number: 103
    Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells
  • Abstract Number: 102
    Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)
  • Abstract Number: 2116
    Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
  • Abstract Number: 1901
    Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
  • Abstract Number: 656
    Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis
  • Abstract Number: 882
    Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
  • Abstract Number: 1888
    Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
  • Abstract Number: 973
    Serum IgG4 Concentrations Differ According to Race and Sex
  • Abstract Number: 1834
    Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
  • Abstract Number: 2913
    Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
  • Abstract Number: 467
    Serum Long-chain n-3 and -6 Fatty Acids Are Associated with Disease Feature at Onset and with 6-month Disease Activity in Early RA: Results from the ESPOIR Cohort
  • Abstract Number: 2496
    Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers
  • Abstract Number: 2428
    Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience
  • Abstract Number: 457
    Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity
  • Abstract Number: 1744
    Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience
  • Abstract Number: 900
    Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
  • Abstract Number: 366
    Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study
  • Abstract Number: 2198
    Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis
  • Abstract Number: 1625
    Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities
  • Abstract Number: 707
    Severity and Evolution over Time of Gastro-Intestinal Involvement in Patients with Systemic Sclerosis in Two Large and Independent Cohorts
  • Abstract Number: 812
    Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism
  • Abstract Number: 1897
    Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
  • Abstract Number: 394
    Sexual Health in 39 Female Patients with Idiopathic Inflammatory Myopathies
  • Abstract Number: 1638
    Sexual Health in 60 Female Patients with Systemic Sclerosis
  • Abstract Number: 2271
    Sexual Health, Intimacy and Rheumatology Practices
  • Abstract Number: 1899
    sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
  • Abstract Number: 2852
    Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
  • Abstract Number: 2833
    Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients
  • Abstract Number: 1830
    Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
  • Abstract Number: 2358
    Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
  • Abstract Number: 1558
    Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
  • Abstract Number: 498
    Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
  • Abstract Number: 1905
    Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)
  • Abstract Number: 2476
    Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
  • Abstract Number: 2734
    Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
  • Abstract Number: 1629
    Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
  • Abstract Number: 146
    Simulated Rheumatology Clinic: Bridging Basic Science and Clinical Application
  • Abstract Number: 1784
    Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions
  • Abstract Number: 1011
    Single Cell RNA Sequencing of Patients with Psoriatic Disease
  • Abstract Number: 2806
    Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis
  • Abstract Number: 1022
    Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages
  • Abstract Number: 2809
    Single-Cell RNA Sequencing of Murine Neutrophils Identifies a Transcriptional Continuum (“Neutrotime”) Across Biological Compartments
  • Abstract Number: 403
    Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
  • Abstract Number: 1760
    Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial
  • Abstract Number: 1454
    Sjӧgren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms
  • Abstract Number: 2739
    Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis
  • Abstract Number: 2397
    Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
  • Abstract Number: 90
    SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation
  • Abstract Number: 2577
    SLE Disease Activity May Be Associated with Choroidal Thickness
  • Abstract Number: 700
    Sleep Quality Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 472
    Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms
  • Abstract Number: 810
    Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase
  • Abstract Number: 246
    Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
  • Abstract Number: 589
    Smoking, Alcohol Intake and Body Mass Index in Prediction of Disease Activity over Time in Early Axial Spondyloarthritis – Results from the SPondyloArthritis Caught Early (SPACE) Cohort
  • Abstract Number: 1228
    Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout
  • Abstract Number: 792
    Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis
  • Abstract Number: 1275
    Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity
  • Abstract Number: 576
    Spinal Bone Formation as Assessed by Low-Dose CT Scan in Patients with Radiographic Axial Spondyloarthritis – Comparison of the Progression Observed in Vertebrae and Facet Joints
  • Abstract Number: 2192
    Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
  • Abstract Number: 2165
    Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults
  • Abstract Number: 2030
    Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption
  • Abstract Number: 2453
    Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
  • Abstract Number: 1893
    Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
  • Abstract Number: 173
    Statin Use Is Associated with Increased Risk of RA in US Population: Results from a Large Nationwide Study
  • Abstract Number: 998
    Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis
  • Abstract Number: 804
    STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
  • Abstract Number: 2759
    Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy
  • Abstract Number: 2236
    Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
  • Abstract Number: 1603
    Stroke Clusters in SLE by Lupus Autoantibodies
  • Abstract Number: 997
    Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis
  • Abstract Number: 709
    Structural Abnormalities of the Optic Nerve Head and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis
  • Abstract Number: 2209
    Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls
  • Abstract Number: 2321
    Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis
  • Abstract Number: 42
    Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
  • Abstract Number: 1815
    Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
  • Abstract Number: 1236
    Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
  • Abstract Number: 1504
    Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
  • Abstract Number: 2756
    Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
  • Abstract Number: 1302
    Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
  • Abstract Number: 1875
    Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
  • Abstract Number: 1308
    Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
  • Abstract Number: 2721
    Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
  • Abstract Number: 2608
    Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions
  • Abstract Number: 346
    Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
  • Abstract Number: 1831
    Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
  • Abstract Number: 2752
    Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging
  • Abstract Number: 129
    Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
  • Abstract Number: 393
    Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody
  • Abstract Number: 2194
    Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers
  • Abstract Number: 1786
    Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury
  • Abstract Number: 873
    Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database
  • Abstract Number: 1114
    Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative
  • Abstract Number: 1674
    Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience
  • Abstract Number: 2646
    Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data
  • Abstract Number: 2669
    Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
  • Abstract Number: 2001
    Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin
  • Abstract Number: 1115
    Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
  • Abstract Number: 2111
    Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
  • Abstract Number: 2246
    Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
  • Abstract Number: 1473
    Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome
  • Abstract Number: 1259
    Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series
  • Abstract Number: 1336
    Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis
  • Abstract Number: 1478
    Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials
  • Abstract Number: 2225
    Systematic Osteoporosis Screening in Chronic Obtructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis
  • Abstract Number: 378
    Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years
  • Abstract Number: 917
    Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors
  • Abstract Number: 2035
    Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell
  • Abstract Number: 1106
    Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock
  • Abstract Number: 1611
    Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?
  • Abstract Number: 2883
    Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
  • Abstract Number: 1459
    Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients
  • Abstract Number: 1648
    Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
  • Abstract Number: 825
    Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades
  • Abstract Number: 738
    Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features: Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis
  • Abstract Number: 2699
    Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
  • Abstract Number: 1737
    Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort
  • Abstract Number: 1902
    Systems Biology in 874 Patients with Primary Sjögren’s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA
Jump to:  View All • a b c d e f g h i j k l m n o p q r [s] t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology